The anti-CD20 antibody-drug conjugates TRS005 in relapse/refractory CD20-positive B-cell non-Hodgkin lymphoma: A multicenter, open-label, single-arm, phase I study
机构:[1]Chinese Acad Med Sci & Peking Union Med Coll, Dept Med Oncol, Beijing Key Lab Clin Study Anticancer Mol Targe, Natl Canc Ctr,Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China[2]Sun Yat Sen Univ, Guangdong Prov Clin Res Ctr Canc, State Key Lab Oncol South China, Canc Ctr, Guangzhou, Peoples R China[3]Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Dept Med Oncol, Canc Hosp, Shenzhen, Peoples R China[4]Chinese Acad Med Sci & Peking Union Med Coll, Shenzhen Hosp, Shenzhen, Peoples R China[5]Henan Prov Canc Hosp, Dept Hematol, Zhengzhou, Peoples R China河南省肿瘤医院[6]Zhengzhou Univ, Henan Canc Hosp, Dept Hematol, Zhengzhou, Peoples R China河南省肿瘤医院[7]Tianjin Med Univ Canc Inst & Hosp, Dept Lymphoma Oncol, Tianjin, Peoples R China[8]Zhengzhou Univ, Dept Oncol, Affiliated Hosp 1, Zhengzhou, Peoples R China[9]Hebei Univ, Dept Med Oncol, Affiliated Hosp, Baoding, Peoples R China医疗肿瘤内科河北大学附属医院[10]Hebei Key Lab Canc Radiotherapy & Chemotherapy, Baoding, Peoples R China[11]ZheJiang Prov peoples Hosp, Dept Hematol, Hangzhou, Peoples R China[12]Chenzhou First Peoples Hosp, Dept Hematol, Chenzhou, Peoples R China[13]Hunan Canc Hosp, Dept Lymphoma & Hematol, Changsha, Peoples R China[14]Shanxi Bethune Hosp, Dept Lymphoma Oncol, Taiyuan, Peoples R China山西白求恩医院[15]Shandong Canc Hosp & Inst, Dept Lymphoma Oncol, Jinan, Peoples R China[16]Jiangxi Canc Hosp, Dept Lymphoma Oncol, Nanchang, Jiangxi, Peoples R China
出处:
ISSN:
基金:
Development Center for Medical Science & Technclogy National Health commission of the People's Republic of china [2014ZX09304313006, 2019ZX09732-001-016]
第一作者机构:[1]Chinese Acad Med Sci & Peking Union Med Coll, Dept Med Oncol, Beijing Key Lab Clin Study Anticancer Mol Targe, Natl Canc Ctr,Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China
推荐引用方式(GB/T 7714):
Shi Yuankai,Li Zhiming,Qin Yan,et al.The anti-CD20 antibody-drug conjugates TRS005 in relapse/refractory CD20-positive B-cell non-Hodgkin lymphoma: A multicenter, open-label, single-arm, phase I study[J].JOURNAL OF CLINICAL ONCOLOGY.2024,42(16):
APA:
Shi, Yuankai,Li, Zhiming,Qin, Yan,Li, Yufu,Zhou, Keshu...&Gui, Lin.(2024).The anti-CD20 antibody-drug conjugates TRS005 in relapse/refractory CD20-positive B-cell non-Hodgkin lymphoma: A multicenter, open-label, single-arm, phase I study.JOURNAL OF CLINICAL ONCOLOGY,42,(16)
MLA:
Shi, Yuankai,et al."The anti-CD20 antibody-drug conjugates TRS005 in relapse/refractory CD20-positive B-cell non-Hodgkin lymphoma: A multicenter, open-label, single-arm, phase I study".JOURNAL OF CLINICAL ONCOLOGY 42..16(2024)